CONFERENCE REPORT Zach Hartman Surveillance of patients with stage I seminoma following orchiectomy can spare a majority of patients from adjuvant chemotherapy with a low risk of relapse, according to results presented at the 2013 ASCO meeting.
RESEARCH REPORT Anna Azvolinsky, PhD Recent studies suggest patients with bladder cancer are not receiving optimal care or the follow-up surveillance as recommended by the National Comprehensive Cancer Network (NCCN).
RESEARCH REPORT Leah Lawrence The use of cannabis among men has been linked to a significantly decreased risk for bladder cancer, according to a recent study; however, no cause and effect association has been found.
REVIEW ARTICLE Brandon P. Verdoorn et al;ONCOLOGY Vol. 27 No. 3 This review focuses on targeted therapies related to pathways of interest for the treatment of advanced urothelial carcinoma, describing the evidence to support further investigation of these approaches.
REVIEW ARTICLE Rian J. Dickstein, Ashish M. Kamat, MD; ONCOLOGY Vol. 25 No. 14 Muscle-invasive bladder cancer is an aggressive and potentially lethal disease. Integration of multimodal therapies, improved surgical techniques, and utilization of targeted agents has tremendously improved outcomes.
The State of Prostate MRI in 2013 Rajan T. Gupta, MD1,
Christopher R. Kauffman, MD1,
Thomas J. Polascik, MD, FACS2,
Samir S. Taneja, MD3,
Andrew B. Rosenkrantz, MD4, April 15, 2013
Our aims in this article are to describe the various imaging sequences that comprise the multiparametric MRI exam, as well as to review current literature on the strengths/weaknesses of these sequences; to delineate strategies for standardizing interpretation and reporting of MRI results; and to expound on the role of prostate MRI in clinical practice.
• The State of Prostate MRI in 2013: Into the Breach • Multiparametric MRI: Standardizations Needed
This review summarizes recent findings in clinical prostate cancer research reported at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology (ASCO) and addresses their relevance to clinical practice.
• Prostate Cancer 2012: Where Do We Stand and Where Are We Heading?
We describe areas where major inroads were initially achieved by targeting angiogenesis and by unraveling
pathways in the heterogeneous tumors of mesenchymal origin—spurred by the identification of c-Kit–activating
mutations in GIST and the regressions that ensued when tumors harboring these mutations were exposed to the
tyrosine kinase inhibitor imatinib (Gleevec).
• Improving Harmonious Precision • Targeted Therapy for Cancer: Asking the Right Questions
A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?
A 28-year-old man presents with testicular pain of several weeks duration. Physical examination discloses the presence of a right testicular mass. Orchiectomy is performed. What is your Diagnosis?
A 63-year-old man presents with symptoms of blood in the urine that has lasted for several days. Cystoscopic examination reveals the presence of a small tumor mass in the trigone of the bladder. Surgical resection is performed.
Recent studies suggest patients with bladder cancer are not receiving optimal care or the follow-up surveillance as recommended by the National... More »
A new study shows that men diagnosed with prostate cancer may do better by substituting carbohydrates and saturated fats with plant-based fats such as... More »
In my experience, being treated for low-volume Gleason 6 tumors is the norm, not the exception, for men in the United States. Surveillance may be... More »
Interesting news in light of a continuing rise in testicular cancer rates: A new genetic link, and evidence in favor of radiation as the standard of... More »
Addition of curcuminoids to treatment with docetaxel was well tolerated and showed promise in improving the response rate to docetaxel “in terms of... More »
Ahead of the 2013 ASCO meeting we highlight some of this year's prostate cancer sessions, many of which focus on how best to use the new agents that have been approved recently, and look into the new drugs and combinations being presented from early trials.